Quantcast
Early Sign Of Pancreatic Cancer Identified By Researchers

Early Sign Of Pancreatic Cancer Identified By Researchers

Dana-Farber Cancer Institute Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer – an upsurge in certain amino...

Latest pancreatic cancer Stories

2014-09-30 08:30:50

Urges provinces to move quickly to fund first new treatment for pancreatic cancer approved in Canada in 20 years HALIFAX, Sept. 30, 2014 /CNW/ - Craig's Cause Pancreatic Cancer Society is very pleased that the pan-Canadian Oncology Review (pCODR) has recognized the clinical benefit of Abraxane (nab paclitaxel) in its recently completed review of the new treatment for pancreatic cancer. It urges Canadian provinces to move quickly to work with the drug's manufacturer to ensure it is...

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-24 23:02:01

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer. New York, New York (PRWEB) September 24, 2014 Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP...

chokeberries
2014-09-20 07:08:16

Becky Attwood, University of Southampton A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology. The study by researchers at King’s College Hospital and the University of Southampton suggests that adding nutraceuticals to chemotherapy cycles may improve the effectiveness of conventional drugs, particularly in hard to treat cancers, such...

2014-09-18 08:30:24

FDA Removes Clinical Hold on Phase 2 Clinical Trial SAN DIEGO, Sept. 18, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with modified FOLFIRINOX...

2014-09-16 23:15:45

Seattle’s own Cancer Research And Biostatistics (CRAB), and Translational Drug Development (TD2) in Scottsdale, would like to jointly announce CRAB’s assumption of responsibility for the PCRT, a world-renowned consortium comprised of a team of pancreatic cancer experts committed to improve treatment outcomes for patients with this deadly cancer. Seattle, WA (PRWEB) September 16, 2014 Seattle’s own Cancer Research And Biostatistics (CRAB), and Translational Drug Development (TD2) in...

2014-09-11 23:01:20

The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2 diabetes drug. New York (PRWEB) September 11, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, including Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-09-08 08:31:27

SAN DIEGO and PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other...

2014-09-03 08:34:15

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed...

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...


Latest pancreatic cancer Reference Libraries

Pancreas
2013-01-02 11:22:15

The pancreas is a digestive and an endocrine organ with both endocrine and exocrine functions. It is about six inches long located in the upper portion of the abdominal cavity. The head of the pancreas lies within the indentation of the duodenum and is connected to it by the pancreatic duct. The uncinate process extends from the head and the neck connects to the body of the pancreas, which lies directly behind the stomach. The tail of the pancreas extends to the left side of the body and is...

More Articles (1 articles) »
Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related